Deputy Chairman Karl Pohl named interim chairman of the Boehringer-Mannheim/DePuy holding company. Board announces March 11 that it "no longer recognizes Mr. Curt Engelhorn" as chairman. "The board emphasizes also that it retains its confidence in the local management of Boehringer Mannheim" and "fully supports" CEO Max Link "and his proposals." Link joined Corange in May and has orchestrated large investments by the company in Protein Design Labs and CellPro
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth